Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy

European Journal of Haematology

Volumn 57, Issue 4, 1996, Pages 320-324

  Niitsu, N ^a   Umeda, M ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

carboplatin; etoposide; high dose Ara C; refractory lymphoma; relapsed lymphoma; salvage chemotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; PEPLEOMYCIN; PREDNISOLONE; PROCARBAZINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0029821081     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01384.x     Document Type: Article

References (18)

1. KLIMO P, CONNORS JM. Updated clinical experience with MACOP-B. Semin Hematol 1987: 24: 26-34.
2. LONGO DL, DE VITA JR VT, DUFFEY PL, et al. Superiority of ProMACE-Cyta BOM over Pro MACE-MOPP in the treatment of advanced diffuse aggressive lymphoma; results of a prospective randomized trial. J Clin Oncol 1991: 9: 25-38.
3. BOYD DB, COLEMAN M, PAPICH SW, et al. COP-BLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. J Clin Oncol 1988: 6: 425-433.
4. VELSQUEZ WS, CABANILLAS F, SALVADOR P, et al. Effective salvage therapy for lymphoma with Cisplatin in combination with high-dose AraC and dexamethasome (DHAP). Blood 1988: 71; 117-122.
5. CABANILLAS F, HAGEMEISTER FB, MCLAUGHLIN P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987: 5: 407-412.
6. HAIM N, ROSENBLATT E, WOLLNER M, BEN-SHAHAR M, EPELBAUM R, ROBINSON E. Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and cisplatin. Cancer Chemother Pharmacol 1992: 30: 243-244.
7. SAEZ RA, SLEASE RB, STRNAD C, SELBY GB, CONFER DL, EPSTEIN RB. High-dose carboplatine, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study. Bone Marrow Trans 1995: 16: 507-514.
8. ARMITAGE JO, FYFE MA, LEWIS I. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen. J Clin Oncol 1984: 2: 898-902.
9. ARAI N, HARA A. UMEDA M, SHIRAI T. COP-BLAM chemotherapy for malignant lymphoma. Rin Ketsu 1991: 31: 951-957.
10. NIITSU N, UMEDA M. Combination chemotherapy with COP-BLAM III for intermediate and high-grade non-Hodgkin's lymphoma. Int J Hematol 1994: 60: 71-78.
11. ARAI N, HARA A, UMEDA M, SHIRAI T. Ifosfamide, mitoxantrone, vindesine, peplomycin, procarbazine, prednisolone (IMV-triple P) chemotherapy for relapsing or refractory malignant lymphoma. Gan to Kagaku Ryoho 1991: 18: 1167-1172.
12. CABANILLAS F, HAGEMEISTR FB, BODEY GP, FREIREICH EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982: 60: 693-697.
13. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A. Reporting results of cancer treatment. Cancer 1981: 47: 207-214.
14. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
15. VELASQUEZ WS, MCLAUGHLIN P, TUCKER S, et al. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994: 12: 1169-1176.
16. NAITO K, KOBAYASHI M, OYAMA A, et al. Phase II study of carboplatin for malignant lymhpoma. Jpn J Cancer Chemother 1988: 15: 2145-2151.
17. BRICE P, MAROLLEAU JP, DOMBRET H, et al. Autologous peripheral blood stem cell transplantation after high-dose therapy in patients with advanced lymphoma. Bone Marrow Trans 1992: 9: 337-342.
18. SICA S, DI MARIO A, SALUTARI P, et al. Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G-CSF in patients with resistant lymphoma. Am J Hematol 1994: 46: 18-23.